The Latest Cardiac and Vascular News
DENVER–(BUSINESS WIRE)–Several Medicare Administrative Contractors (MACs) have officially approved Artificial Intelligence-enabled Quantitative Coronary Topography (AI-QCT) scans for Medicare recipients with stable and acute symptoms suspicious of coronary artery disease. Cleerly, the company on a mission to eradicate heart attacks, requested the decision on MAC coverage in February of 2023 to expand […]
Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations
Tricuspid valve regurgitation can lead to enlarged heart, fatigue and heart failure; the condition affects 1.6 million Americans PITTSBURGH, Oct. 10, 2024 /PRNewswire-PRWeb/ — The cardiac team from Allegheny General Hospital (AGH), the academic flagship facility of Allegheny Health…
OKLAHOMA CITY, Oct. 9, 2024 /PRNewswire/ — OU Health, the flagship academic health system of the University of Oklahoma, has performed its first pediatric heart transplant in decades at Oklahoma Children’s Hospital OU Health, marking a significant milestone in pediatric cardiac care for…
Medtronic plc, a global leader in healthcare technology, today announced the launch of the Avalus Ultra™ Bioprosthesis valve in Western Europe during the EACTS annual congress in Lisbon. The Avalus Ultra valve, engineered for ease of use at implant and lifetime patient management, is Medtronic’s most advanced surgical aortic tissue […]
Medical device company marks trial milestone in the evaluation of its embolic protection device, creates expert advisory board as it navigates growth opportunity TAMPA, Fla., Oct. 8, 2024 /PRNewswire/ — EMBLOK™ (emblok.com), a privately held medical device company developing the most…
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it is set to initiate a Phase 2 clinical trial of MANP for the treatment of Resistant Hypertension (BOLD-HTN) supported by a recent round of financing.
Program reduced all-cause 30-day readmissions for CHF patients by 50 percent using a combination of AI-powered technology and remote human care teams. SOUTHBRIDGE, Mass., Oct. 8, 2024 /PRNewswire/ — UMass Memorial Health – Harrington (“Harrington”), the health and wellness provider for…
MINNEAPOLIS, Oct. 8, 2024 /PRNewswire/ — 4C Medical Technologies, Inc. (“4C Medical”), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has commenced enrollment in the ATLAS (A Transseptal Left Atrial System for Treatment of…
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the “Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. “For decades, managing fluid removal in patients with […]
